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BACKGROUND: Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with cardiovascular risks and 
poor renal outcomes. However, whether elevated suPAR levels are associated with 24-hour blood pressure patterns or kidney 
disease progression in patients with chronic kidney disease (CKD) is unclear.
METHODS AND RESULTS: A total of 751 patients with CKD stage 1 to 5 were recruited from CMERC-HI (Cardiovascular and 
Metabolic Disease Etiology Research Center–High Risk) cohort study (2013–2018). The relationship of serum suPAR levels to 
24-hour blood pressure parameters and CKD progression was analyzed. The median serum suPAR level was 1439.0 (inter-
quartile range, 1026.2–2150.1) pg/mL, and the mean estimated glomerular filtration rate was 52.8±28.5 mL/min per 1.73 m2 
at baseline. Patients with higher suPAR levels had significantly higher levels of office, 24-hour, daytime, and nighttime systolic 
blood pressure and nighttime diastolic blood pressure than those with lower suPAR levels. The highest suPAR tertile was as-
sociated with an increased risk of a reverse dipping pattern (odds ratio, 2.93; 95% CI, 1.27–6.76; P=0.01). During a follow-up 
of 43.2 (interquartile range, 27.0–55.6) months, the CKD progression occurred in 271 (36.1%) patients. The highest suPAR 
tertile was significantly associated with higher risk of CKD progression than the lowest tertile (hazard ratio [HR], 2.09; 95% 
CI, 1.37–3.21; P=0.001). When the relationship was reevaluated with respect to each dipping pattern (dipper, extreme dipper, 
nondipper, and reverse dipper), this association was consistent only in reverse dippers in whom the risk of CKD progression 
increased (HR, 1.43; 95% CI, 1.02–2.01; P=0.03) with every 1-unit increase in serum suPAR levels.
CONCLUSIONS: Elevated suPAR levels are independently associated with CKD progression, and this association is prominent 
in reverse dippers.
Key Words: chronic kidney disease ■ dipping pattern ■ progression of kidney disease ■ soluble urokinase-type plasminogen activator 
receptor
Chronic kidney disease (CKD), defined as reduced kidney function or kidney damage, is one of the major public health concerns worldwide.1 The prevalence of CKD affects >10% of the worldwide population.2,3 Patients with CKD are at a high risk for adverse outcomes, including cardiovascular disease 
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(CVD), end-stage renal disease (ESRD), and death.4–8 
Approximately half of individuals with advanced CKD 
stages die because of CVD; thus, preventing the pro-
gression of CKD is crucial in this population. Despite 
the extensive resources devoted to CKD treatment, 
the incidence of progression to ESRD and the mor-
tality risk remain high. Thus, it is important to identify 
the risk factors of kidney function decline in patients 
with CKD.
Soluble urokinase-type plasminogen activator recep-
tor (suPAR), a circulating form of a glycosyl-phosphati-
dylinositol–anchored 3-domain membrane protein, has 
been acknowledged to be associated with the patho-
genesis of kidney disease, including focal segmental 
glomerulosclerosis and diabetic nephropathy, via inter-
fering podocyte migration and apoptosis.9–12 suPAR is 
expressed in a variety of cells, such as immune cells, 
endothelial cells, and podocytes. suPAR has also been 
reported to be involved in the pathogenesis of various 
inflammatory diseases, and elevated suPAR levels 
contribute to poor outcomes in diverse patient popula-
tions.10,13,14 Individuals with high suPAR levels are at an 
increased risk for cardiovascular events, independent 
of traditional risk factors.15–17 Recently, suPAR is sug-
gested to be associated with kidney function decline 
in patients with CKD.18–20 In addition, previous studies 
have found that elevated suPAR levels are significantly 
associated with endothelial dysfunction caused by 
chronic inflammation, which is the cornerstone of vas-
cular complication or subclinical organ damage in both 
the general population and patients with CKD.21,22
Although suPAR has been suggested to have a role 
in endothelial dysfunction and progression of CKD in 
patients with reduced kidney function, it is unclear 
whether suPAR levels, kidney function decline, and 24-
hour blood pressure (BP) patterns, which are the rep-
resentatives of endothelial dysfunction, have a mutual 
interrelationship. Therefore, the objective of this study 
was to assess whether suPAR is useful for predicting 
CKD progression and to evaluate its association with 
24-hour BP patterns in patients with CKD.
METHODS
Study Population
Study subjects were recruited from the CMERC-HI 
(Cardiovascular and Metabolic Disease Etiology 
Research Center–High Risk) cohort study (clini caltr 
ials.gov: NCT02003781). The detailed profiles and 
methods of how the CMERC-HI study was designed 
have been previously described elsewhere and are 
summarized in Data S1.23 The study cohort included 
3270 subjects who met the inclusion criteria from 
December 2013 to June 2018. In this study, we se-
lected patients with CKD stage 1 to 5 (defined by 
Kidney Disease Improving Global Outcomes guide-
line24; presenting at least >3 months of proteinuria or 
estimated glomerular filtration rate [eGFR] <60 mL/
min per 1.73 m2) and excluded those with ESRD re-
quiring long-term dialysis or those who had under-
gone kidney transplantation, those with inadequate 
samples, and those with missing ambulatory BP 
monitoring profiles or baseline and follow-up cre-
atinine data (Figure  1). Finally, 751 subjects were 
analyzed. All subjects voluntarily participated and 
provided informed consent. This study was per-
formed in accordance with the principles of the 
Declaration of Helsinki and was approved by the in-
stitutional review board of Yonsei University Health 
System Clinical Trial Center (4-2013-0581). The data 
that support the findings of this study are avail-




• In patients with chronic kidney disease, the el-
evated serum soluble urokinase-type plasmino-
gen activator receptor levels are associated with 
increased levels of office, 24-hour, daytime, and 
nighttime systolic blood pressure and nighttime 
diastolic blood pressure and increased risk of a 
reverse dipping pattern.
• The higher serum soluble urokinase-type plas-
minogen activator receptor levels are signifi-
cantly associated with higher risk of progression 
of chronic kidney disease.
• The association of high soluble urokinase-type 
plasminogen activator receptor levels and in-
creased risk of chronic kidney disease progres-
sion is prominent in reverse dippers.
What Are the Clinical Implications?
• These findings support the importance of serum 
soluble urokinase-type plasminogen activator 
receptor levels, which can be used to predict 
the progression of kidney disease in patients 
with chronic kidney disease, especially in those 
with altered circadian blood pressure patterns.
Nonstandard Abbreviations and Acronyms
CMERC-HI  Cardiovascular and Metabolic 
Disease Etiology Research 
Center–High Risk
suPAR soluble urokinase-type 
plasminogen activator receptor
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Data Collection
Demographic and socioeconomic data, including 
age, sex, smoking status, alcohol intake, family his-
tory, and medical histories, were collected at enroll-
ment. Anthropometric parameters, such as height, 
body weight, and body mass index, were measured 
by skilled evaluators. Smoking and alcohol history 
was assessed on the basis of the answer from survey 
questionnaires and classified into 2 groups: current or 
former versus never smoker or drinker. Hypertension 
was defined as a self-reported hypertension his-
tory, antihypertensive medication use, or 24-hour BP 
≥130/80 mm Hg at the time of visit. Diabetes mellitus 
was defined as self-reported diabetes mellitus history, 
antidiabetic medication use, fasting plasma glucose 
levels >126  mg/dL, or hemoglobin A1c ≥6.5%. CVD 
was defined as a composite of a medical history of 
coronary artery occlusive disease, ischemic heart dis-
ease, congestive heart failure, and cerebrovascular ac-
cident. The following biochemical data were collected 
by testing fasting blood samples: blood urea nitrogen, 
creatinine, hemoglobin, glucose, hemoglobin A1c, al-
bumin, total cholesterol, triglyceride, high-density lipo-
protein cholesterol, low-density lipoprotein cholesterol, 
and CRP (C-reactive protein). Serum creatinine level 
was determined using the rate-blanked compensated 
Jaffe kinetic method with the Roche reagent CREA 
(Roche, Basel, Switzerland) and the Roche Calibrator 
for Automated Systems, which is traceable to an iso-
tope dilution mass spectrometry reference method, in 
the Hitachi Automatic Analyzer (Hitachi, Tokyo, Japan). 
eGFR was calculated using the CKD–Epidemiology 
Collaboration equation.25 Urine samples were col-
lected in the morning after the first voiding. Fresh urine 
samples were analyzed using URISCAN Pro II (YD 
Diagnostics Corp, Seoul, Korea). Presence of albumi-
nuria was assessed by urine albumin/creatinine ratio.
Measurement of Circulating suPAR Levels
Fasting venous blood samples were obtained, and 
serum and plasma were stored at −80°C on study en-
rollment. The serum levels of suPAR were measured 
with a commercially available ELISA kit (suPARnostic 
kit; ViroGates, Copenhagen, Denmark), which has a 
lower limit of detection of 100 pg/mL (according to the 
manufacturer, the intra-assay variation is 2.75% and 
the interassay variation is 9.17%). The study subjects 
were classified into tertiles based on baseline serum 
suPAR levels.
BP Measurements
The 24-hour BP measurements were obtained using 
the Takeda TM-2430 instrument (A&D Medical, 
Figure 1. Study subjects.
BP indicates blood pressure; CKD, chronic kidney disease; ESRD, end-stage renal disease; KT, kidney 
transplantation; suPAR, soluble urokinase-type plasminogen activator receptor; T1, tertile 1; T2, tertile 2; 
and T3, tertile 3.
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Tokyo, Japan), with readings taken every 30 minutes. 
Ambulatory BP monitoring was considered adequate 
if the monitor had been worn for a full 24-hour period 
and if there was at least 70% of expected measure-
ments with 20 acceptable readings between 9 am and 
9 pm (daytime) and 7 acceptable readings between 
1 am and 6 am (nighttime).26 Ambulatory BP readings 
were averaged for the 24-hour, daytime, and nighttime 
values. On the basis of nighttime fall in ambulatory 
systolic BP, patients were classified as dipper (night-
time BP fall, 10%–20%), extreme dipper (nighttime fall 
in BP, >20%), nondipper (nighttime BP fall, 0%–10%), 
and reverse dipper (nighttime fall in BP, <0%).27,28
Office BP was obtained using a validated automatic 
device (HEM 7080-IC; Omron, Kyoto, Japan), which 
was programmed to automatically measure the sitting 
BP of a person at 5, 7, and 9 minutes.29 After position-
ing the participant in the sitting position and the right 
arm supported at heart level and setting the device, a 
trained nurse left the participants alone in the exam-
ination room. After a 5-minute rest, automatic BP mea-
surements at 2-minute intervals were obtained in the 
examination room. After 3 measurements, a trained 
nurse recorded the BP data. The mean of the 3 BP 
readings was used as the office BP.
Study End Point
The study end point was the progression of CKD. 
The level of eGFR was assessed every 3 months, and 
median number of eGFR measurements was 11.7 (in-
terquartile range, 5.0–15.0). CKD progression was de-
fined as the composite outcome of the development of 
eGFR <60 mL/min per 1.73 m2 or a 30% decrease of 
eGFR from baseline in patients with CKD stage 1 to 2 
and a 50% decrease of eGFR or progression to ESRD 
in those with CKD stage 3 to 5. The renal events were 
assessed by 2 researchers independently, and the oc-
currence of ESRD was decided with electronic medical 
records review.
Statistical Analysis
Continuous variables are expressed as mean±SD, 
and categorical variables are expressed as abso-
lute numbers with percentages. All data were tested 
for normality before the statistical analysis. The 
Kolmogorov-Smirnov test was performed to deter-
mine the distribution normality. Between-group com-
parisons were performed using ANOVA or Student t 
test for continuous variables with a normal distribu-
tion, and the χ2 test or Fisher exact test for categori-
cal variables. Data with a nonnormal distribution are 
presented as medians with interquartile ranges and 
compared using the Mann-Whitney U test or Kruskal-
Wallis test. Logistic regression analysis was performed 
to identify the relationship between suPAR levels and 
24-hour BP patterns (dipping, extreme dipping, non-
dipping, and reverse dipping). Cumulative survival 
rates were estimated using Kaplan-Meier analysis 
and the log-rank test. Survival time was defined as 
the time from baseline to the onset of outcome or the 
last follow-up. Subjects who were lost to follow-up or 
death were censored at the last examination date. Cox 
proportional hazard models were constructed to de-
termine the significant predictive values of suPAR for 
the study outcome. Variables that showed statistical 
significance in the univariable analyses or were con-
sidered to have clinical significance were included in 
the multivariable models, such as age, sex, smoking 
status, body mass index, history of hypertension, dia-
betes mellitus, or CVD, baseline levels of hemoglobin, 
total cholesterol, and CRP, albuminuria, and 24-hour 
systolic BP. Results were expressed as hazard ratios 
and 95% CIs. To test the relationship between the risk 
of CKD progression and suPAR levels as a continuous 
variable, restricted cubic spline analyses using Cox 
proportional hazard model were conducted. Before in-
vestigating the interactive effect of kidney function on 
the impact of suPAR levels on outcomes, the multicol-
linearity between eGFR and serum suPAR levels was 
assessed on the basis of the variance inflation factor.30 
We found that the variance inflation factor was in the 
acceptable range (<2.0) to adjust eGFR for showing 
the effect of suPAR levels on the study outcome. To 
evaluate the effect of 24-hour BP patterns on the as-
sociation between suPAR levels and kidney function, 
the study subjects were classified according to the 
24-hour BP patterns (dipping, nondipping, and reverse 
dipping), and the predictive value of suPAR on CKD 
progression was analyzed. The mediation analysis 
was performed, and an interaction term was deter-
mined to investigate the effect of dipping patterns on 
the association between kidney function and suPAR 
levels. For all analyses, P<0.05 was considered statisti-
cally significant. All statistical analyses were performed 
using IBM SPSS software for Windows version 25.0 




The baseline characteristics of the study subjects, 
according to the tertiles of baseline serum suPAR 
levels, are shown in Table  1. The mean age of the 
study subjects was 61.4±11.4 years, and 395 (52.6%) 
subjects were men. The median serum suPAR level 
was 1439.0 (interquartile range, 1026.2–2150.1) pg/
mL, and the mean eGFR level was 52.8±28.5 mL/min 
per 1.73 m2 at baseline. The higher tertiles of suPAR 
showed significantly increased levels of office systolic 
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BP, and the prevalence of diabetes mellitus was 
higher in tertiles with higher suPAR than in the low-
est suPAR tertile. With respect to laboratory findings, 
the mean eGFR level was lower and the urine albu-
min/creatinine ratio was higher in tertiles with higher 
suPAR than in the lowest suPAR tertile. The levels of 
hemoglobin, serum albumin, and high-density lipo-
protein cholesterol were lower, and the CRP level was 
higher, in tertiles with higher suPAR than in the lowest 
suPAR tertile.
Association of 24-Hour BP Parameters 
With Serum suPAR Levels
We further evaluated the association between 24-hour 
BP parameters and serum suPAR levels (Table 2). At 
baseline, tertiles with higher suPAR showed signifi-
cantly higher levels of office, 24-hour, daytime, and 
nighttime systolic BP than the lower suPAR tertiles. 
However, with respect to diastolic BP, only nighttime 
diastolic BP was significantly higher in patients in 
Table 1. Baseline Characteristics, According to Tertiles of Serum suPAR Concentration
Characteristic Entire Cohort (n=751)
Baseline Serum suPAR Concentration, pg/mL
P Value<1162 (n=250) 1163–1863 (n=251) ≥1874 (n=250)
Demographic data
Age, y 61.4±11.4 60.7±10.9 61.5±11.9 62.1±11.2 0.40
Men 395 (52.6) 142 (56.8) 131 (52.2) 122 (48.8) 0.07
BMI, kg/m2 25.2±3.7 25.5±3.3 25.2±3.9 25.0±3.9 0.23
Smoking status 428 (57.0) 145 (58.0) 133 (53.0) 150 (60.0) 0.39
Alcohol status 272 (36.2) 88 (35.2) 83 (33.1) 101 (40.4) 0.17
SBP, mm Hg 130.1±18.2 125.5±14.6 129.0±17.4 135.9±20.5 <0.001
DBP, mm Hg 75.6±11.7 74.9±9.3 76.3±10.8 75.5±11.7 0.33
CKD stages <0.001
I 97 (12.9) 74 (29.6) 21 (8.4) 02 (0.8)
II 180 (24.0) 98 (39.2) 57 (22.7) 25 (10.0)
IIIa 161 (21.4) 62 (24.8) 68 (27.1) 31 (12.4)
IIIb 116 (15.4) 12 (4.8) 59 (23.5) 45 (18.0)
IV 130 (17.3) 2 (0.8) 40 (15.9) 88 (35.2)
V 67 (8.9) 2 (0.8) 6 (2.4) 59 (23.6)
Comorbidities
Hypertension 669 (89.1) 219 (87.6) 222 (88.4) 228 (91.2) 0.20
Diabetes mellitus 363 (48.3) 108 (43.2) 105 (41.8) 150 (60.0) <0.001
Dyslipidemia 434 (57.8) 157 (62.8) 140 (55.8) 137 (54.8) 0.70
CHF 9 (1.2) 3 (1.2) 1 (0.4) 5 (2.0) 0.41
CAD 43 (5.7) 21 (8.4) 9 (3.6) 13 (5.2) 0.06
CVA 36 (4.8) 13 (5.2) 12 (4.8) 11 (4.4) 0.68
Laboratory data
eGFR, mL/min per 1.73 m2 52.8±28.5 75.1±23.6 52.2±22.7 31.1±19.9 <0.001
UACR, mg/g creatinine 305.4 (63.2–953.7) 96.0 (34.7–401.6) 225.8 (63.8–793.0) 774.9 (196.7–1928.8) <0.001
Hemoglobin, g/dL 12.2±3.0 12.9±3.9 12.6±2.6 11.1±1.8 <0.001
Albumin, g/dL 3.9±0.5 4.3±0.3 4.1±0.3 3.9±0.5 <0.001
Total cholesterol, mg/dL 171.7±38.9 174.2±39.1 172.7±36.7 168.2±40.9 0.20
LDL-C, mg/dL 84.1±39.5 82.7±39.2 85.1±37.7 84.6±41.6 0.78
HDL-C, mg/dL 42.0±19.7 44.9±22.0 43.4±18.3 37.7±17.9 <0.001
Fasting glucose, mg/dL 114.9±35.9 114.9±31.2 114.6±33.0 115.0±42.5 0.90
HbA1c, % 6.0±1.8 5.9±1.8 5.9±1.8 6.2±1.8 0.13
CRP, mg/dL 0.80 (0.50–1.60) 0.70 (0.40–1.20) 0.90 (0.50–1.70) 0.90 (0.50–2.37) 0.001
Data are presented as mean±SD, median (interquartile range), or number (percentage). CKD stages were defined on the basis of Kidney Disease: Improving 
Global Outcomes guidelines 2012. BMI indicates body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; 
CRP, C-reactive protein; CVA, cerebrovascular accident; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL-
C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure; suPAR, soluble urokinase-type plasminogen 
activator receptor; and UACR, urine albumin/creatinine ratio.
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higher suPAR tertiles than in those in the lowest suPAR 
tertile. Furthermore, we classified the subjects accord-
ing to 24-hour BP patterns into dippers, extreme dip-
pers, nondippers, and reverse dippers, and evaluated 
the association with serum suPAR levels. In patients 
with higher suPAR levels, the proportion of dippers 
was significantly lower (P=0.01) and that of reverse dip-
pers was higher than in patients with the lowest suPAR 
level (P<0.001).
Finally, as the reverse dipping pattern was signifi-
cantly associated with higher suPAR levels, we per-
formed logistic regression analysis to further investigate 
the association of serum suPAR levels with dipping 
patterns (Table  3). In multivariable logistic regression 
analysis, the highest tertile of suPAR was associated 
with a 2.93-fold increased risk of the reverse dipping 
pattern (95% CI, 1.27–6.76; P=0.01). This association 
was consistent when serum suPAR levels were treated 
as a continuous variable, in which each 1-unit increase 
in log-transformed baseline suPAR increased the risk 
of a reverse dipping pattern by 2.10-fold (95% CI, 1.22–
3.60; P=0.01).
Association Between Serum suPAR 
Levels and CKD Progression
At baseline, negative correlation was observed be-
tween kidney function with eGFR as continuous vari-
able and suPAR levels (β, −27.65; 95% CI, −30.28 to 
−25.01; P<0.001) (Table S1). During a median follow-
up of 43.2 (interquartile range, 27.0–55.6) months, 
progression of CKD occurred in 271 (36.1%) patients. 
The incidence of CKD progression was higher in pa-
tients in higher tertiles of suPAR than in those in the 
lowest suPAR tertile (15.2%, 27.1%, and 48.8% in 
the lowest, middle, and highest suPAR tertiles, re-
spectively; P for trend <0.001) (Table 4). The Kaplan-
Meier curve showed that the highest tertile of suPAR 
was significantly associated with an increased risk of 
CKD progression (P<0.001; Figure  2). Furthermore, 
multivariable Cox proportional hazard analyses were 
performed to assess the association between serum 
suPAR levels and CKD progression. The highest tertile 
of suPAR was significantly associated with a 2.09-fold 
increased risk of CKD progression compared with the 
lowest tertile (95% CI, 1.37–3.21; P=0.001). This as-
sociation was consistent when the serum suPAR level 
was treated as a continuous variable in which each 
1-unit increase of log-transformed serum suPAR level 
increased the risk of CKD progression by 1.29-fold 
(95% CI, 1.02–1.62; P=0.03) (Table 4).
Effect of Dipping Pattern on the 
Association Between suPAR Levels and 
CKD Progression
As suPAR has a role in endothelial dysfunction and 
CKD progression in patients with reduced kidney 
function, and we have confirmed that higher serum 
suPAR levels were associated with an increased risk 
for a reverse dipping pattern, we assessed whether 
suPAR is useful for predicting CKD progression in 
Table 2. BP Parameters at 24 Hours, According to Tertiles of Serum suPAR Concentration
Parameter Entire Cohort (n=751)
Baseline Serum suPAR Concentration, pg/mL
P Value<1162 (n=250) 1163–1863 (n=251) ≥1874 (n=250)
Office BP, mm Hg
SBP 130.1±18.2 125.5±14.6 129.0±17.4 135.9±20.5 <0.001
DBP 75.6±11.7 74.9±9.3 76.3±10.8 75.5±11.7 0.33
Pulse rate 70.4±12.0 69.6±11.8 70.6±12.0 70.8±12.2 0.51
Ambulatory BP, mm Hg
24-h SBP 131.3±15.1 127.8±13.3 129.7±14.4 136.4±16.3 <0.001
24-h DBP 77.6±8.6 77.0±7.3 77.4±7.9 78.4±10.2 0.15
Daytime SBP 135.0±16.8 131.8±16.4 133.9±14.6 139.4±18.4 <0.001
Daytime DBP 80.0±9.8 79.7±9.3 80.3±8.4 80.2±9.8 0.77
Nighttime SBP 123.8±18.6 119.1±16.8 122.5±16.2 129.8±20.8 <0.001
Nighttime DBP 72.5±9.7 71.1±9.3 72.5±9.1 73.8±10.7 0.01
Dipping patterns
Dipper 325 (43.3) 120 (48.0) 112 (44.6) 93 (37.2) 0.01
Extreme dipper 54 (7.2) 23 (9.2) 13 (5.2) 18 (7.2) 0.39
Nondipper 331 (44.1) 107 (42.8) 116 (46.2) 108 (43.2) 0.92
Reverse dipper 93 (12.4) 22 (8.8) 23 (9.2) 48 (19.2) <0.001
Data are presented as mean±SD or number (percentage). BP indicates blood pressure; DBP, diastolic BP; SBP, systolic BP; and suPAR, soluble urokinase-
type plasminogen activator receptor.
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association with 24-hour BP patterns. First, we per-
formed mediation analysis to investigate the effect 
of dipping pattern (dipping, nondipping, and reverse 
dipping) on the association between CKD progres-
sion and suPAR levels; outcome variable for the anal-
ysis was CKD progression, predictor variable was 
suPAR levels, and mediator variable was dipping pat-
tern. The indirect effect of suPAR on CKD progres-
sion was statistically significant (β, 0.18; P<0.001). 
However, the effect of suPAR levels on progression 
of CKD completely disappeared after adding dipping 
pattern as mediator (β, 0.06; P=0.07), suggesting that 
dipping pattern mediates between suPAR levels and 
kidney function decline.
When the subjects were divided according to 
the dipping pattern, the association between higher 
suPAR levels and increased risk for CKD progression 
was consistent only in reverse dippers in whom the 
risk of CKD progression was increased by 1.43-fold 
(95% CI, 1.02–2.01; P=0.03) with every 1-unit increase 
in log-transformed serum suPAR levels (P for interac-
tion=0.004) (Figure 3).
DISCUSSION
In this prospective cohort of patients with CKD, we 
identified a mutual interrelationship between elevated 
serum suPAR levels, reverse dipping BP pattern, and 
CKD progression. In particular, higher serum suPAR 



























































































































































































































































































































































































































































































































































































































































Figure 2. Kaplan-Meier curve of the risk for chronic kidney 
disease (CKD) progression, according to tertiles of soluble 
urokinase-type plasminogen activator receptor levels.
Note: Progression of CKD was defined as development of 
estimated glomerular filtration rate (eGFR) <60  mL/min per 
1.73 m2 or 30% decrease of eGFR than baseline in patients with 
CKD stage 1 to 2 and 50% decrease of eGFR or progression 
to end-stage renal disease in those with CKD stage 3 to 5. T1 
indicates tertile 1; T2, tertile 2; and T3, tertile 3.
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progression, and this association was more prominent 
in reverse dippers.
CKD is a public health problem that affects 10% of 
adults in the Western world and confers a high risk of 
complications, such as the development of ESRD and 
cardiovascular events.2,6,31 Hypertension is a major risk 
factor for the development and progression of CKD.32 
In contrast, CKD is both a common cause and a se-
quel of uncontrolled hypertension.32 Uncontrolled BP 
consequently contributes to poor outcome in patients 
with CKD.33,34 In addition, patients with CKD show al-
teration in the circadian BP pattern, primarily a reduced 
or absent nighttime decrease in BP levels (nondipper 
or reverse dipper), which contributes to target organ 
damage and major cardiovascular events.35 The patho-
physiological features underlying the altered circadian 
BP patterns in patients with CKD are multifactorial and 
remain incompletely understood. Several factors or 
mechanisms, including increased sodium and fluid vol-
ume retention, impaired baroreceptor sensitivity, altered 
sympathetic nervous system activity, activation of the re-
nin-angiotensin system, endothelial dysfunction, oxida-
tive stress, chronic inflammation, and increased arterial 
stiffness, have been proposed to explain the altered BP 
circadian rhythm in patients with CKD.36 Among these 
factors, endothelial dysfunction is a common event in 
the development of hypertension.37 In all stages of CKD, 
decreased kidney function is closely associated with 
abnormal circadian BP variation and a nondipping pat-
tern.38,39 In patients with hypertension, nocturnal BP is 
elevated and endothelial function deteriorates in parallel 
with decreasing kidney function.40,41
suPAR is a novel marker of chronic inflammation 
and endothelial dysfunction.14 It is expressed in vari-
ous cells, including immune cells, endothelial cells, and 
podocytes.9,42 The circulating and membrane-bound 
forms play a direct role in regulating cell adhesion or mi-
gration, and are also involved in inflammatory processes 
and endothelial damage in tissues.43 Chronic inflamma-
tion and endothelial dysfunction are the cornerstone of 
the development of CVD; thus, suPAR is a good prog-
nostic marker for the development of CVD.15–17 In the 
kidneys, suPAR regulates the permeability of the glo-
merular filtration barrier, and several lines of evidence 
about pathogenic role of suPAR in kidney disease have 
been mainly found in studies of focal segmental glomer-
ulosclerosis, in which suPAR was revealed to activate 
integrin in podocytes, leading to foot process efface-
ments and proteinuria.11 Elevated suPAR levels have 
also been implicated in the pathogenesis of diabetic 
nephropathy.44 In animal models of diabetic kidney dis-
ease, blockade of integrin was protective against kidney 
function decline.45 Moreover, suPAR mediates kidney in-
jury via several molecular mechanisms. suPAR interacts 
with a variety of molecules, inducing podocyte dysfunc-
tion, and mediates the development or progression of 
CKD.18,20,46 Recently, Hayek et al reported that elevated 
suPAR levels in 3683 subjects with normal kidney func-
tion were independently associated with incident CKD 
and an accelerated decline in eGFR.20 Moreover, Lv et al 
showed that elevated suPAR levels were independently 
associated with an increased risk of progression to 
ESRD in Chinese patients with CKD.18
In the present study, in line with previous studies, pa-
tients with elevated suPAR levels showed a significantly 
increased risk of CKD progression, regardless of their 
baseline kidney function. Interestingly, this association 
was more prominent in patients showing a reverse dip-
ping pattern. A reverse dipping pattern or increased night-
time BP and elevated suPAR levels both imply chronic 
Figure 3. Cubic spline curves for risk of chronic kidney disease progression, according to baseline serum soluble 
urokinase-type plasminogen activator receptor (suPAR) concentration in dipper (A), nondipper (B), and reverse dipper (C).
Notes: Hazard ratio per 1 increase of log-transformed baseline suPAR (P for interaction=0.004) and models were adjusted for 
demographic factors (age, sex, smoking status, and body mass index), comorbidities (history of hypertension, diabetes mellitus, and 
cardiovascular disease), laboratory tests (hemoglobin, total cholesterol, CRP [C-reactive protein], and baseline estimated glomerular 
filtration rate), and 24-hour systolic blood pressure.
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inflammation and endothelial dysfunction. Patients with a 
reverse dipping pattern and elevated suPAR levels are at 
high risk of target organ damage, such as kidney injuries 
and destruction of vascular structures.47,48 Thus, patients 
with both increased nighttime BP and elevated suPAR 
levels are prone to glomerular vasculature destruction 
and podocyte injuries, which eventually lead to progres-
sion of CKD. Consequently, our findings provide addi-
tional insights into the predictive role of suPAR in kidney 
disease by showing that altered BP patterns in patients 
with CKD are involved in the association between ele-
vated suPAR levels and deterioration of kidney function.
This study had some limitations. First, serum suPAR 
levels may have been affected by kidney function. A pre-
vious study demonstrated a negative correlation between 
suPAR and eGFR levels, in which high serum suPAR 
levels were associated with decreased eGFR levels.49 
However, Hayek et al46 recently reported that the negative 
correlation between suPAR level and baseline eGFR was 
weak in subjects with eGFR >90 mL/min per 1.73 m2. 
Moreover, they showed that a considerable proportion of 
participants (>30%) with normal kidney function showed 
elevated suPAR levels in the absence of any sepsis or 
cancer. Therefore, high suPAR levels are unlikely to be the 
consequence of decreased kidney function. In the pres-
ent study, subjects with elevated suPAR levels showed 
decreased baseline eGFR, as observed in previous stud-
ies. Nevertheless, we adjusted the baseline eGFR levels 
in the prediction models and further investigated the in-
teractive effect of kidney function on the impact of suPAR 
levels on outcomes. The multicollinearity, assessed using 
the variance inflation factor between baseline eGFR and 
serum suPAR levels, was acceptable in our study. Thus, 
we inferred that elevated serum suPAR levels are unlikely 
to be a simple result of decreased kidney function and 
may be related to the underlying pathogenic mechanism 
in the progression of kidney disease. Second, the study 
cohort was relatively small and involved a single ethnicity. 
Therefore, there is a limit to the generalizability of the re-
sults. Third, because of the observational study design, 
a clear causality between serum suPAR levels and CKD 
progression cannot be deduced. Finally, a single mea-
surement of baseline suPAR level was used. Further stud-
ies with serial measurements of suPAR levels, taking into 
account the changes over time, are needed.
In conclusion, we identified a mutual interrelationship 
between elevated serum suPAR levels, a reverse dipping 
BP pattern, and progression of CKD. In particular, a high 
serum suPAR level was associated with an increased 
risk of CKD progression, and this association was more 
prominent in reverse dippers in this study. Elevated suPAR 
levels can be used to predict the progression of kidney 
disease in patients with CKD, especially in those with al-
tered circadian BP patterns. Future studies are needed 
to confirm whether an elevated suPAR level serves as 
early treatment and intervention in patients with CKD.
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Study profiles of the Cardiovascular and Metabolic Disease Etiology Research Center-
High Risk (CMERC-HI) 
 
The CMERC-HI study is a prospective cohort study that included patients at a high risk of 
developing cardiovascular diseases (CVDs) and was designed to establish an individualized 
preventive strategy for CVDs and cerebrovascular diseases. The inclusion criteria were as 
follows: high-risk hypertension with estimated glomerular filtration rates (eGFRs) of >60 
mL/min/1.73 m2 and at least one or more target organ damage, or eGFRs of ≤60 mL/min/1.73 
m2 and diabetes mellitus with albuminuria; end‐stage renal disease under dialysis treatment or 
kidney transplantation >3 months prior; acute myocardial infarction among relatives aged 
younger than 55 years (for men) or 65 years (for women); asymptomatic atherosclerotic 
(abdominal aorta diameter of ≥3 cm or ankle-brachial index of <0.9, carotid plaque or carotid 
intima‐media thickness of ≥0.9 mm, asymptomatic old cerebrovascular accident, or >30% 
stenosis in at least one major coronary artery); rheumatic arthritis aged >40 years and taking 
methotrexate or steroid; and atrial fibrillation with CHA2DS2‐VASc score of ≥1. The 
exclusion criteria were acute coronary syndrome, symptomatic coronary artery disease, 
symptomatic peripheral artery disease, and symptomatic heart failure histories; <6-month life 
expectancy owing to severe non-CVD; pregnancy or breastfeeding status; and contrast allergy 
and related adverse events histories.
Table S1. The association between baseline serum suPAR concentration and eGFR.  
 
 Model 1 Model 2 Model 3 Model 4 
 β (95% CI) P β (95% CI) P β (95% CI) P β (95% CI) P 
suPAR* -29.75 (-32.44- -27.04) <0.001 -30.60 (-33.11- -28.09) <0.001 -30.98 (-33.46- -28.51) <0.001 -27.65 (-30.28- -25.01) <0.001 
* Linear regression analysis was performed for eGFR and log-transformed baseline suPAR, β = coefficient 
Model 1: Unadjusted  
Model 2: Adjusted for demographic factors (age, sex, smoking status, and BMI) 
Model 3: Adjusted for Model 2 + comorbidities (history of hypertension, diabetes, and CVD) 
Model 4: Adjusted for Model 3 + laboratory tests (hemoglobin, total cholesterol, and CRP), albuminuria, and 24-hr SBP 
suPAR, Soluble Urokinase-Type Plasminogen Activator Receptor; CI, confidence interval; eGFR, estimated glomerular filtration rate; BMI, body mass 
index; CVD, cardiovascular disease; CRP, C-reactive protein; SBP, systolic blood pressure 
